Trials / Unknown
UnknownNCT01818505
The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 210 (estimated)
- Sponsor
- National Taiwan University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, the investigators will analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. The investigators expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.
Detailed description
Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, we'll analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/ asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. We expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities. Patient eligibility: 1. Patients with gout 2. Patients with asymptomatic hyperuricemia 3. Patients of osteoarthritis but without hyperuricemia and gout Exclusion Criteria: Patients younger than 20 years old
Conditions
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2015-12-01
- First posted
- 2013-03-26
- Last updated
- 2014-04-14
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01818505. Inclusion in this directory is not an endorsement.